Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Trial details

Who runs it

Chugai Pharmaceutical

Trial code

NCT06371417EU 2023-507692-21-00

Record updated

22 July 2026

Original description

This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).Read full original descriptionShow less

Phase 1b Open-label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)

This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).

Exclusion: Planned surgery during the study; Illicit drug or alcohol abuse; Positive for human immunodeficiency virus antibody; Treatment with investigational therapy within 28 days or 5 half-lives; Previous and current treatment with anti-C1s antibody at any time; Other complement inhibitors within 3 months; Patients who receive any treatments which fall into the Prohibited Therapy Criteria; APS cohort:; 1) APS associated with other systemic autoimmune disease; 2) Acute thrombosis (arterial or venous acute thrombosis diagnosis) within 30 days before screening; 3) Patients with thrombotic APS without any anticoagulation treatment; 4) Treatment with prohibited medications; BP cohort:; ・ 1) Initiation of treatment with or increase in the dose of systemic or topical corticosteroid within 2 weeks; 2) Current treatment with a drug that may cause or exacerbate BP unless the dose has been stable; 3) Initiation of treatment with topical calcineurin inhibitor, or topical phosphodiesterase (PDE) 4 inhibitor within 7 days; 4) Treatment with prohibited medications; BS cohort:; ・ 1) BS-related active major organ involvement-ocular lesions requiring immunosuppressive therapy, pulmonary (e.g., pulmonary artery aneurysm), vascular (e.g., thrombophlebitis), gastrointestinal (e.g., ulcers along the gastrointestinal tract), and central nervous systems (e.g., meningoencephalitis) manifestations; 2) History of venous or arterial thrombosis within 1 year; 3) Treatment with prohibited medications; DM cohort:; ・ 1) PhGA-VAS improvement >= 3, or clinically relevant improvement between screening and baseline; 2) Overlap myositis (except for overlap with Sjögren's syndrome), connective tissue disease associated DM, inclusion body myositis, polymyositis, IMNM, juvenile DM or drug-induced myopathy; 3) Cancer-associated myositis; 4) Significant muscle damage; 5) Past history of severe Interstitial lung disease flare, severe non-infectious lung inflammation which required active intervention, or multiple episodes of lung disease; 6) Severe respiratory muscle weakness; 7) Severe bulbar palsy; 8) Treatment with prohibited medications; IMNM cohort:; ・ 1) PhGA-VAS improvement >= 3, or clinically relevant improvement between screening and baseline; ・ 2) Overlap myositis (except for overlap with Sjögren's syndrome), connective tissue disease associated DM, inclusion body myositis, polymyositis, juvenile DM or druginduced myopathy; ・ 3) Cancer-associated myositis; ・ 4) Significant muscle damage; ・ 5) Past history of severe Interstitial lung disease (ILD) flare, severe non-infectious lung inflammation which required active intervention, or multiple episodes of lung disease; ・ 6) Severe respiratory muscle weakness; ・ 7) Severe bulbar palsy; ・ 8) Treatment with prohibited medications; History of anaphylaxis or hypersensitivity to a biologic agent; Active infection requiring systemic antiviral, antibiotics or antifungal; Clinical diagnosis of autoimmune diseases other than the target disease (except for Sjögren's syndrome in DM and IMNM); Positive for hepatitis B surface antigen; Positive for hepatitis C virus antibody; Evidence of current infection with tuberculosis; History of cancer within 5 years; Any serious medical condition or abnormality in clinical laboratory tests that precludes the patient's safe participation in and completion of the study; Patients with an elevated alanine aminotransferase or aspartate aminotransferase > 1.5 × ULN in combination with an elevated total bilirubin > 1.5 × ULN; ITP cohort:; ・ 1) Secondary ITP; ・ 2) Clinical diagnosis or history of Myelodysplastic Syndrome or autoimmune hemolytic anemia; ・ 3) History of venous or arterial thrombosis within 12 months; ・ 4) Patients who experienced major bleeding within 4 weeks; 5) Treatment with prohibited medications; 6) Any laboratory test results meet either of the following criteria at screening:; Hemoglobin <10 g/dL; Thyroid-stimulating hormone >= 10 μIU/mL; Pregnant or breastfeeding, or intending to become pregnant; Clinically significant ECG abnormalities.

Signed informed consent form; Age ≥ 18 and ≤ 85 at the time of signing informed consent form with Karnofsky score ≥ 60 % at screening; Ability to comply with the study protocol; For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods; For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm; APS cohort: Established primary APS defined by the following criteria (at least one of the laboratory criteria and one of the clinical criteria must be met):; Laboratory criteria (aPL profile); Persistently positive LA test; Persistently positive aCL IgG isotype; Persistently positive aβ2GPI IgG isotype; Clinical criteria; Livedoid vasculopathy and presence of skin ulcer; Acute/chronic aPL nephropathy; BP cohort:; Predominant cutaneous lesions 2) Diagnosis with BP with following assessments positive:; Positive direct immunofluorescence, and either; Positive indirect immunofluorescence, or; Positive serology on ELISA for BP180 autoantibody 3) BPDAI score >= 20 4) Weekly average of daily Peak Pruritus NRS >=4 5) Accept to take photograph of bullous lesions; BS cohort:; Diagnosed with BS; Oral ulcers that occurred at least 3 times in the previous 12 month period; Have at least 2 oral ulcers over the 4 weeks prior to screening; Have at least 2 oral ulcers at Week 0; Have prior treatment with at least 1 non-biologic BS therapy; Patients who need systemic therapy as whose oral or mucocutaneous ulcers cannot be adequately controlled by topical therapy; DM cohort:; Diagnosed with definite or probable inflammatory myopathies and categorized as DM; Patients with inadequate response to corticosteroids and/or immune-suppressants or intolerance to DM therapies; MMT-8 score < 142, with at least one abnormality in the following Core Set Measures:; PtGA-VAS >= 2 cm; PhGA-VAS >= 2 cm; Global extra-muscular activity >= 2 cm; At least one muscle enzyme > 1.5 times ULN; HAQ >= 0.25; Moderate to severe DM defined as CDASI activity score > 14; IMNM cohort:; Clinically Diagnosed with IMNM as anti-HMGCR myopathy or anti-SRP myopathy; CK > 1,000 U/L; Patients who have an inadequate response to corticosteroids and/or immunesuppressants or intolerance to IMNM therapies; MMT-8 score < 142; ITP cohort:; Confirmed diagnosis of persistent/chronic ITP based on the following criteria:; ITP defined per the current guidelines; Platelet count <= 30 × 10\^9/L on 2 consecutive occasions; Lack of an sustained adequate platelet count response to a thrombopoietin receptor agonist and at least one other ITP treatment or a second TPO-RA; A history of response with an platelet counts increase more than 20 × 10\^9/L from baseline by at least one prior line of therapy.

ClinicalTrials.gov NCT06371417 · EU CTIS 2023-507692-21-00